PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.
P/B ratio for PaxMedica, Inc. Common Stock (PXMD)
P/B ratio as of 2023: 0.37
According to PaxMedica, Inc. Common Stock's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.37. At the end of 2022 the company had a P/B ratio of 163.10.
P/B ratio history for PaxMedica, Inc. Common Stock from 2018 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 0.37 |
| 2022 | 163.10 |
| 2021 | -5.72 |
| 2020 | -12.50 |
| 2019 | -8505.18 |
| 2018 | 0.00 |